CXCR4 and Alzheimer disease: Plerixafor (rank 1, CXCR4 antagonist): While FDA-approved for stem cell mobilization, plerixafor’s potential AD relevance is based on CXCR4’s role in neuroinflammation and microglial activation pathways implicated in disease progression.